Cg Oncology, Inc. · NASDAQ:CGON
Cg Oncology — NCSAUA 2025
12 slides from Cg Oncology's conference presentation, Oct 16, 2025
Slide 1: BOND-003 Cohort P Trial in Progress: Cretostimogene for BCG-Unresponsive NMIBC
Trial in Progress: BOND-003 Cohort P- A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High-Risk, Papillary-Only, BCG-Unresponsive NMIBC Piyush Agarwal, MD Director, Bladder Cancer Program UChicago Medicine Presented at NCSAUA 2025; October 16, 2
Slide 2: Disclosures
Disclosures • CG Oncology – no conflict of interest 2
Slide 3: Cretostimogene Selectively Targets Rb-E2F Pathway Altered Cancers
Cretostimogene Selectively Targets Rb-E2F Pathway Altered Cancers • Oncolytic immunotherapy with dual MOA o Viral replication results in tumor lysis o Stimulation of immune response • Conditionally replicating, highly immunogenic adenovirus o Under regulation of the human E2F-1 promoter o Encodes GM
Slide 4: BCG-UR NMIBC Study Design Considerations
BCG-UR NMIBC Study Design Considerations Recommendations from 2018/2024 FDA Guidance • Single-arm trials appropriate for BCG- UR NMIBC studies • Primary efficacy endpoints: o CR in patients with CIS o Time-to-event endpoint for patients with completely resected Ta/T1 disease 4
Slide 5: Consistent and Compelling CR & 24-Month Durability Data
Consistent and Compelling CR & 24-Month Durability Data Overall Complete Response CR CR Rate, % CR by K -M Est, % 75.5% 100 Landmark (95% CI) (95% CI) (95% CI, 66.3 % - 83.2 %) 46.4% (36.9, 56.1) 12-month 50.7% (40.9, 59.8) 75 51 out of 110 patients Overall CR Rate (%) 41.8% (32.5, 51.6) 24 -month 1
Slide 6: Cretostimogene Demonstrates Best in Class Duration of Response in HR BCG-UR NMIBC
Cretostimogene Demonstrates Best in Class Duration of Response in HR BCG-UR NMIBC Estimated DOR Probability at 12 Months Estimated DOR Probability at 24 Months 64.1% Duration of Response Probability (%) (95% CI: 52.4-73.7) 58.3% (95% CI: 46.3-68.5) • Median DoR is 27.9 months and ongoing (95% CI 14.
Slide 7: Favorable and Well-Tolerated Safety Profile
Favorable and Well-Tolerated Safety Profile Cretostimogene (n=112) Preferred Term (MedDRA v.26.1) Any Grade (%) Grade ≥ 3 • Most AEs were Grade 1-2 Patients with ≥ 1 TRAE 71 (63.4%) 0 (0) • 0% Grade ≥ 3 TRAEs or deaths Treatment-Related AE reported in > 10% patients • Median time to TRAE resolution:
Slide 8: Significant Unmet Need for BCG-UR Papillary NMIBC
Significant Unmet Need for BCG-UR Papillary NMIBC • Current FDA approved agents DFS/HG-RFS Pembrolizumab 5 Nadofaragene 6,7 N-803+BCG 8 TAR-200 9 for patients with HR BCG-UR 3 months, % 87.7 72.9 Not Reported Not Reported NMIBC with CIS +/- Ta/T11 (95% CI) (80.7-92.3) (58.2-84.7) 6 months, % 53.1 62
Slide 9: Phase 3 Cretostimogene Monotherapy for High-Risk, BCG-Unresponsive NMIBC, Papillary Only
Phase 3 Cretostimogene Monotherapy for High-Risk, BCG-Unresponsive NMIBC, Papillary Only BCG-Unresponsive NMIBC Cretostimogene Grenadenorepvec Primary Endpoint: Single-Arm, Open-Label, IVE Administration HG Event-Free Survival Population Study Design / Regimen Additional Endpoints • Enrollment Compl
Slide 10: First Results: BOND-003 Cohort P HR NMIBC BCG-Unresponsive HG Ta/T1
First Results: BOND-003 Cohort P HR NMIBC BCG-Unresponsive HG Ta/T1 Kaplan-Meier Estimate for High Grade Recurrence-Free Survival • Data from first 24 treated patients HG Recurrence-Free Survival (%) • Strong early responses with 90.5% HG-RFS (95% CI: 77.9-100%) at 3 and 9 Months • Very well-tolerat
Slide 11: BOND-003 Cohort P: Trial In Progress
BOND-003 Cohort P: Trial In Progress • First sites opened and patients enrolled March 2024 • 35+ sites selected across North America and Japan • Completed enrollment • Topline results 2H2025 11
Slide 12: Acknowledgements
Acknowledgements All Bladder Cancer Patients and Their Families The Study Coordinators and Nurses Key Collaborators CG Oncology Andy Darilek Mark Tyson, Mayo, AZ Pradnya Gunjotikar Woodson Smelser, WU, MO Jee-Hyun Kim Rian Dickstein, CUA, MD Kristen Scholz Daniel Zainfeld, Urology SA, TX Rebecca Tre